The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000831381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
15/06/2026
Date registered
Help: Date registered
10/07/2026
Date last updated
Help: Date last updated
10/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Does physiotherapy management of the upper neck reduce the frequency and burden of migraine headache?
Scientific title
The effect of cervical musculoskeletal management on the frequency and burden of episodic migraine among participants with or without identifiable cervical musculoskeletal dysfunction who experience migraines: a mixed-methods study
Additional trial identifiers [1] 317418 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Migraine 342084 0
Cervical musculoskeletal dysfunction 342558 0
Condition category
Condition code
Physical Medicine / Rehabilitation 338201 338201 0 0
Physiotherapy
Musculoskeletal 338703 338703 0 0
Other muscular and skeletal disorders
Neurological 338704 338704 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Mixed methods (Interventional study and interviews)
The interventional component is a clinical trial with a within-subject repeated measures design investigating physiotherapy musculoskeletal management strategies focussed on upper cervical rotation on the frequency and burden of migraine.
Participants in the interventional trial will be stratified into two cohorts based on the presence or absence of identifiable cervical musculoskeletal dysfunction:
• Cohort A (main study group): Participants with identified cervical musculoskeletal dysfunction
• Cohort B (embedded pilot study): Participants without identifiable cervical musculoskeletal dysfunction will receive the same interventions as Cohort A to provide preliminary evidence regarding the relevance of the physical assessment process in patient screening
The intervention will be multimodal physiotherapy management (manual therapy mobilisation techniques, related home exercises and education). The same treatment process will be provided by a physiotherapist with over 30 years experience to each participant who will receive 4 x 1 hour individual physiotherapy sessions (1 per week for 4 weeks) at a private physiotherapy practice. Due to variability in participants initial status, symptoms and irritability the dosage of manual therapy and exercises, and pace of progression, will be determined by the treating physiotherapy. The manual therapy will take 30-40 minutes with 10 minutes each of exercise and education. The exercises involve range of movement and self 'mobilisation with movement' techniques for the neck and cervicothoracic area combined with postural exercises. The clinic appointments will be scheduled to suit the participants availability and there are reminders for home exercises as part of a daily diary that will be used to collect data.
• An embedded qualitative sub-study will be conducted using interviews at approximately 3 months post-treatment of participants from both Cohort A & B.
Intervention code [1] 334210 0
Treatment: Other
Description of the comparator or control
There is no control group. A within-subject design will identify the responder rate for the participants with identified musculoskeletal impairment (Cohort A) as the primary outcome. The responder rate of the pilot group (Cohort B) with no identified cervical dysfunction will provide preliminary evidence regarding the relevance of cervical impairment identification.
Control group
Active

Outcomes
Primary outcome [1] 345568 0
Migraine frequency (Responder analysis - Binary)
Timepoint [1] 345568 0
Migraine frequency will be calculated based on the daily recording of symptoms over 3 distinct 28 day recording periods. The baseline measure will be the 28 days of the 'treatment as usual' period. Migraine frequency will also be measured with the daily diary through the 28 days of the treatment period. The 3-month assessment window will span weeks 10–14 post-treatment to provide a 28-day observation period centred on the 3-month timepoint (Primary End-point)
Secondary outcome [1] 462186 0
Headache frequency (Responder analysis - Binary)
Timepoint [1] 462186 0
Headache frequency will be calculated based on the daily recording of symptoms over 3 distinct 28 day recording periods. The baseline measure will be the 28 days of the 'treatment as usual' period. Headache frequency will also be measured with the daily diary through the 28 days of the treatment period. The 3-month assessment window will span weeks 10–14 post-treatment to provide a 28-day observation period centred on the 3-month timepoint
Secondary outcome [2] 462196 0
Migraine frequency (days with migraine symptoms)
Timepoint [2] 462196 0
Migraine frequency will be calculated based on the daily recording of symptoms over 3 distinct 28 day recording periods. The baseline measure will be the 28 days of the 'treatment as usual' period. Migraine frequency will also be measured with the daily diary through the 28 days of the treatment period. The 3-month assessment window will span weeks 10–14 post-treatment to provide a 28-day observation period centred on the 3-month timepoint
Secondary outcome [3] 462197 0
Headache frequency (days with headache symptoms)
Timepoint [3] 462197 0
Headache frequency will be calculated based on the daily recording of symptoms over 3 distinct 28 day recording periods. The baseline measure will be the 28 days of the 'treatment as usual' period. Headache frequency will also be measured with the daily diary through the 28 days of the treatment period. The 3-month assessment window will span weeks 10–14 post-treatment to provide a 28-day observation period centred on the 3-month timepoint
Secondary outcome [4] 462198 0
Migraine intensity
Timepoint [4] 462198 0
Migraine intensity will be calculated based on the daily recording of symptoms over 3 distinct 28 day recording periods. The baseline measure will be the 28 days of the 'treatment as usual' period. Migraine intensity will also be measured with the daily diary through the 28 days of the treatment period. The 3-month assessment window will span weeks 10–14 post-treatment to provide a 28-day observation period centred on the 3-month timepoint
Secondary outcome [5] 462199 0
Headache Intensity
Timepoint [5] 462199 0
Headache intensity will be calculated based on the daily recording of symptoms over 3 distinct 28 day recording periods. The baseline measure will be the 28 days of the 'treatment as usual' period. Headache intensity will also be measured with the daily diary through the 28 days of the treatment period. The 3-month assessment window will span weeks 10–14 post-treatment to provide a 28-day observation period centred on the 3-month timepoint
Secondary outcome [6] 462200 0
Migraine medication
Timepoint [6] 462200 0
Medication use will be calculated based on the daily recording of symptoms over 3 distinct 28 day recording periods. The baseline measure will be the 28 days of the 'treatment as usual' period. Medication use will also be measured with the daily diary through the 28 days of the treatment period. The 3-month assessment window will span weeks 10–14 post-treatment to provide a 28-day observation period centred on the 3-month timepoint
Secondary outcome [7] 462237 0
Impact of the headache on daily functioning
Timepoint [7] 462237 0
Pre-treatment commencement (Day 1 of intervention) Immediately Post-treatment completion (after 4 weeks of treatment) 3 months post-treatment completion 6 months post-treatment completion* 12 months post treatment completion* *= if results at earlier timepoints indicate continued analysis is warranted
Secondary outcome [8] 462238 0
Neck pain related disability in daily activities
Timepoint [8] 462238 0
Pre-treatment commencement (Day 1 of intervention) Immediately Post-treatment completion (after 4 weeks of treatment) 3 months post-treatment completion 6 months post-treatment completion* 12 months post treatment completion* *= if results at earlier timepoints indicate continued analysis is warranted
Secondary outcome [9] 462239 0
Participants rating of the effect of the intervention
Timepoint [9] 462239 0
Immediately Post-treatment completion (after 4 weeks of treatment) 3 months post-treatment completion 6 months post-treatment completion* 12 months post treatment completion* *= if results at earlier timepoints indicate continued analysis is warranted
Secondary outcome [10] 462240 0
Cervical Flexion Rotation Test (CFRT)
Timepoint [10] 462240 0
Baseline (Day 1 of treatment as usual period) Pre-treatment commencement (Day 1 of intervention period) Immediately Post-treatment completion (after 4 weeks of treatment)
Secondary outcome [11] 462253 0
Cervical Active range of movement
Timepoint [11] 462253 0
Baseline (Day 1 of treatment as usual period) Pre-treatment commencement (Day 1 of intervention period) Immediately Post-treatment completion (after 4 weeks of treatment)
Secondary outcome [12] 462254 0
Patient expectations for the treatment to provide benefit
Timepoint [12] 462254 0
Baseline (Day 1 of treatment as usual period) Pre-treatment commencement (Day 1 of intervention period) Immediately Post-treatment completion (after 4 weeks of treatment)
Secondary outcome [13] 462255 0
Differences in treatment experiences between responders and non-responders (qualitative analysis)
Timepoint [13] 462255 0
3 months Post-treatment completion
Secondary outcome [14] 462256 0
Quality of Life
Timepoint [14] 462256 0
Pre-treatment commencement (Day 1 of intervention) Immediately Post-treatment completion (after 4 weeks of treatment) 3 months post-treatment completion 6 months post-treatment completion* 12 months post treatment completion* *= if results at earlier timepoints indicate continued analysis is warranted
Secondary outcome [15] 462257 0
Inter-ictal (between migraine event) burden
Timepoint [15] 462257 0
Pre-treatment commencement (Day 1 of intervention) Immediately Post-treatment completion (after 4 weeks of treatment) 3 months post-treatment completion 6 months post-treatment completion* 12 months post treatment completion* *= if results at earlier timepoints indicate continued analysis is warranted
Secondary outcome [16] 463853 0
Cervical movement control
Timepoint [16] 463853 0
Baseline (Day 1 of treatment as usual period) Pre-treatment commencement (Day 1 of intervention period) Immediately Post-treatment completion (after 4 weeks of treatment)
Secondary outcome [17] 463854 0
Cervical proprioception
Timepoint [17] 463854 0
Baseline (Day 1 of treatment as usual period) Pre-treatment commencement (Day 1 of intervention period) Immediately Post-treatment completion (after 4 weeks of treatment)
Secondary outcome [18] 463855 0
Perceived role of the neck in the migraine symptoms
Timepoint [18] 463855 0
Baseline (Day 1 of treatment as usual period) Pre-treatment commencement (Day 1 of intervention period) Immediately Post-treatment completion (after 4 weeks of treatment)

Eligibility
Key inclusion criteria
• Unilateral migraine as the dominant headache consistent with the ICHD-3 migraine criteria
• Headache frequency of at least 4 days per month (but not more than 15)
• A history of regular neck pain
Physical examination inclusion criteria:
• Arm 1 (Cohort A) require unilateral C1/2 segmental movement dysfunction identified on physical assessment with abnormal Cervical Flexion Rotation Test (CFRT) and C1/2 positive joint palpation
Arm 2 (Cohort B) need to have no identified cervical segmental movement dysfunction with a normal CFRT.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• A maximum number of 15 headache days per month
• Specific disorders and congenital conditions of the cervical spine (e.g., past cervical spine surgery, infection, tumour, fracture, diffuse idiopathic skeletal hyperostosis, cervical degenerative joint disease, stenosis)
• Receiving any manual therapy treatment to the neck or head in the past 3 months
• A change in migraine medication in the past 3 months
• Neck and head trauma requiring medical care/hospitalisation in the past 3 months
• Contraindications to study treatments (e.g., inflammatory cervical arthropathies, cervical instability, severe osteoporosis, vertigo, dizziness)
• Surgery in Temporomandibular joint (TMJ) area in past 6 months
• A neurological history with current symptoms (multiple sclerosis, Amyotrophic lateral sclerosis (ALS), Parkinson’s, myelopathy, seizures, cervical radiculopathy, herniated disc, thoracic outlet syndrome, brachial plexus neuropathy)
• A cardiovascular history with current symptoms (history of stroke, transient ischaemic attacks, stage 2 hypertension, taking anticoagulant medication, syncope, myocardial infarction, haemophilia)
• Pregnancy, trying to get pregnant, or within 3 months postpartum
• Active or pending medical litigation, personal injury, workers compensation, or disability compensation related to a head or neck injury
• Cancer in the past five years
On physical examination:
• hyperalgesia at > 3 cervical levels on a passive accessory manual examination (as this could indicate central sensitisation processes were a dominant component).
• Test positive to Vertebrobasilar insufficiency (VBI) screening which is a safety concern for the vertebral artery during upper cervical rotation to ensure end of range positions do not provoke symptoms of cerebral ischaemia.



Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Different groups of participants (i.e. with or without identifiable cervical musculoskeletal dysfunction) receive the same intervention: multimodal physiotherapy (manual therapy, exercises and education)
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 321993 0
University
Name [1] 321993 0
The University of Queensland
Country [1] 321993 0
Australia
Primary sponsor type
University
Name
The University of Queensland
Address
Country
Australia
Secondary sponsor category [1] 324868 0
None
Name [1] 324868 0
Address [1] 324868 0
Country [1] 324868 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320653 0
The University of Queensland Human Research Ethics Committee B
Ethics committee address [1] 320653 0
Ethics committee country [1] 320653 0
Australia
Date submitted for ethics approval [1] 320653 0
24/04/2026
Approval date [1] 320653 0
19/06/2026
Ethics approval number [1] 320653 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150758 0
Mr Peter Farmer
Address 150758 0
Brisbane Physiotherapy and Podiatry, 45 Mollison St, West End, Brisbane, 4101
Country 150758 0
Australia
Phone 150758 0
+61 7 3778 6444
Fax 150758 0
Email 150758 0
Contact person for public queries
Name 150759 0
Peter Farmer
Address 150759 0
Brisbane Physiotherapy and Podiatry, 45 Mollison St, West End, Brisbane, 4101
Country 150759 0
Australia
Phone 150759 0
+61 7 3778 6444
Fax 150759 0
Email 150759 0
Contact person for scientific queries
Name 150760 0
Peter Farmer
Address 150760 0
Brisbane Physiotherapy and Podiatry, 45 Mollison St, West End, Brisbane, 4101
Country 150760 0
Australia
Phone 150760 0
+61 7 3778 6444
Fax 150760 0
Email 150760 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.